Pages that link to "Q33147483"
Jump to navigation
Jump to search
The following pages link to Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. (Q33147483):
Displaying 50 items.
- Prostacyclin for pulmonary hypertension in adults (Q24246933) (← links)
- Inhaled treprostinil: a therapeutic review (Q24601864) (← links)
- Pharmacotherapy of systemic sclerosis (Q24629481) (← links)
- Health-related quality of life in patients with pulmonary arterial hypertension (Q24814151) (← links)
- Insight into Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (PAH-CHD): Classification and Pharmacological Management from a Pediatric Cardiological Point of View (Q26749283) (← links)
- The limits of oral therapy in pulmonary arterial hypertension management (Q26773209) (← links)
- Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension (Q26775860) (← links)
- Pulmonary arterial hypertension: the burden of disease and impact on quality of life (Q26775863) (← links)
- The molecular targets of approved treatments for pulmonary arterial hypertension (Q26798308) (← links)
- Treatment of idiopathic/hereditary pulmonary arterial hypertension (Q26823608) (← links)
- Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011 (Q26830290) (← links)
- Portopulmonary hypertension: an update (Q27000393) (← links)
- Pharmacotherapy for pulmonary hypertension (Q27022763) (← links)
- The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) (Q27497418) (← links)
- Pulmonary arterial hypertension: a comparison between children and adults (Q27687320) (← links)
- Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension (Q28069093) (← links)
- A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy (Q28072562) (← links)
- A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration (Q28074915) (← links)
- Treprostinil for the treatment of pulmonary arterial hypertension (Q28281899) (← links)
- Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension (Q30244352) (← links)
- Pulmonary arterial hypertension: an update (Q30472109) (← links)
- Recent trends in pulmonary arterial hypertension (Q30475192) (← links)
- Pulmonary arterial hypertension: the clinical syndrome (Q30583630) (← links)
- Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data (Q31108228) (← links)
- Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. (Q33156291) (← links)
- Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial (Q33156379) (← links)
- Pulmonary hypertension: diagnosis and management (Q33157071) (← links)
- Pediatric pulmonary arterial hypertension. (Q33163446) (← links)
- Sildenafil for pulmonary hypertension (Q33213984) (← links)
- Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs [corrected] (Q33405650) (← links)
- Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion (Q33430747) (← links)
- Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion (Q33431527) (← links)
- Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy? (Q33532813) (← links)
- The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease (Q33608215) (← links)
- Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials (Q33670265) (← links)
- Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials (Q33673947) (← links)
- New approaches to the treatment of pulmonary hypertension: from bench to bedside (Q33690368) (← links)
- Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis (Q33715766) (← links)
- Severe pulmonary arterial hypertension associated with congenital cardiac shunts: evolution under specific treatment (Q33786574) (← links)
- Prognostic value of echocardiographic changes in patients with pulmonary arterial hypertension receiving parenteral prostacyclin therapy (Q33787275) (← links)
- Therapy for pulmonary arterial hypertension associated with systemic sclerosis (Q33805746) (← links)
- Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery (Q33805945) (← links)
- Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics (Q33806168) (← links)
- Prenatal programming of pulmonary hypertension induced by chronic hypoxia or ductal ligation in sheep (Q33806234) (← links)
- Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies. (Q33810499) (← links)
- Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review. (Q33816571) (← links)
- The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension (Q33844740) (← links)
- Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries (Q33890202) (← links)
- Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases (Q33965825) (← links)
- Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension (Q33965859) (← links)